June 16, 2025 – Commercial Times / Reporter: Hui-Jung Tu
Uni-Pharma (Stock Code: 6621), a rising star under Genovate-Bio Group (4130), announced on June 16 that it has secured the exclusive distribution rights to CASTOMIZE—a lightweight, breathable, and customizable orthopedic cast developed by a Singaporean company. Following its strong market performance with Adept anti-adhesion solution from Baxter Healthcare, this new partnership is expected to further drive Uni-Pharma’s business growth.
According to Chairman Dr. Cheng Chen, CASTOMIZE utilizes advanced 4D printing technology and smart, non-metallic materials, which allow for clear X-ray imaging without interference. Compared to similar products, it offers faster and easier thermoplastic molding, a better anatomical fit, and features a skin-friendly antibacterial soft material infused with silver ions that also provides cushioning flexibility.
Dr. Chen further explained that the ventilated grid design of CASTOMIZE is key to its outstanding breathability, making it ideal for Taiwan’s hot and humid climate. The cast weighs only one-fourth the weight of traditional plaster casts, reducing physical burden on the patient. Its buckle system makes it easy to wear and remove while minimizing the risk of loosening, offering patients a more comfortable and secure fracture recovery experience.
CASTOMIZE recently received the 2025 APAC Insider Singapore Business Award, which recognizes achievements in technological innovation, sustainability, and economic impact. Its advanced design and high product quality have garnered widespread international recognition.
Currently available in a wrist model, the Singaporean development team has already begun working on ankle, elbow, and pediatric-sized versions, with an official market launch planned for late 2025. These new additions will provide parents with more advanced and comfortable orthopedic options for their children.
